Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Bariatric Surgery in Children. (BASIC)

25. august 2021 opdateret af: Maastricht University Medical Center

The BASIC Trial. Morbid Obesity in Children and Adolescents: a Prospective Randomised Trial of Conservative Treatment Versus Surgery

Rationale:

In the Western world overweight and obesity is an increasing problem both in adults and in children. In youth, it is associated with early death and a number of co-morbidities including metabolic and endocrine changes, increased inflammatory status, cardiovascular abnormalities, nonalcoholic fatty liver disease, and impaired quality of life.

The standard treatment for morbid obesity in children is by combined life style interventions. However, the medium and long term effects of dietetic interventions, behaviour therapy and medication is relatively poor. In adults bariatric surgery shows good results with up to 30% weight reduction in 3 years. The preliminary results in youth are similar, but surgery in this age group is relatively uncommon. In the Netherlands surgery in this age group is only allowed in clinical trials, until the benefits and risks have been established. (National Health Authorities)

Objective:

To determine if surgery gives a superior weight and body mass index (BMI) reduction than combined life style interventions in adolescents with morbid obesity and to assess its effect on obesity associated co-morbidity.

Study design:

Prospective randomised interventional study.

Study population:

Morbidly obese children, aged 14 - 16 years, with sex and age adjusted BMI >40 kg/m2 or >35 kg/m2 with co-morbidity.

Intervention:

Bariatric surgery by laparoscopic adjustable gastric band (LAGB) or combined life style interventions

Main study parameters/endpoints:

Primary endpoints: weight loss, loss of excess weight, loss of excess BMI. Secondary endpoints: Body composition, pubertal development, metabolic and endocrine changes, inflammatory status, cardiovascular abnormalities, non-alcoholic steatohepatitis, brain development, quality of life, and behaviour changes. The potential complications of surgery are monitored.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

60

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Limburg
      • Maastricht, Limburg, Holland, 6202ZA
        • Maastricht University Medical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

14 år til 16 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Aged 14 to 16
  • Age and sex adjusted BMI >40 kg/m2 or >35 kg/m2 with associated co-morbidity.

    * Associated co-morbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseudotumor cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-alcoholic steatohepatitis and dyslipidemia.

  • > 1 year multidisciplinary organized weight reducing attempts with less than 5% weight loss
  • Demonstrate decisional capacity

Exclusion Criteria:

  • Psychologically not suitable
  • Pre-menarche or bone age <15 years in boys
  • Obesity associated to other disorders such as hypothyroidism
  • Syndromal disorders such as Prader-Willi syndrome
  • Severe cardiorespiratory impairment (ASA class 3 or higher)
  • Insufficiently fluid in the Dutch language
  • Unwillingness to adhere to follow-up programmes

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Kontrolgruppe
Control group will receive standard therapy consisting of combined lifestyle interventions.
Eksperimentel: Laparoscopic adjustable gastric band
Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
Control group will receive standard therapy consisting of combined lifestyle interventions.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Weight
Tidsramme: 6 months
Weight loss, excess weight loss and loss of excess BMI.
6 months
Weight
Tidsramme: 12 months
Weight loss, excess weight loss and loss of excess BMI.
12 months
Weight
Tidsramme: 24 months
Weight loss, excess weight loss and loss of excess BMI.
24 months
Weight
Tidsramme: 36 months
Weight loss, excess weight loss and loss of excess BMI.
36 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Body composition
Tidsramme: 12 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
12 months
Pubertal development
Tidsramme: 6 months
Follow-up of hormonal status and Tanner stages.
6 months
Metabolic and endocrine changes
Tidsramme: 6 months
6 months
Inflammatory status
Tidsramme: 6 months
Measurement of serum inflammatory markers.
6 months
Cardiovascular abnormalities
Tidsramme: 6 months
6 months
Non-alcoholic fatty liver disease
Tidsramme: 6 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
6 months
Quality of life changes
Tidsramme: 6 months
6 months
Behaviour changes
Tidsramme: 6 months
Measuring impulsivity and positive reward dominance with a computer task.
6 months
Operative complications
Tidsramme: up to 36 months
Early and late complications are being monitored
up to 36 months
Effects on sleep architecture
Tidsramme: 6 months
6 months
Brain development
Tidsramme: 6 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
6 months
Body composition
Tidsramme: 24 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
24 months
Body composition
Tidsramme: 36 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
36 months
Pubertal development
Tidsramme: 12 months
Follow-up of hormonal status and Tanner stages.
12 months
Pubertal development
Tidsramme: 24 months
Follow-up of hormonal status and Tanner stages.
24 months
Pubertal development
Tidsramme: 36 months
Follow-up of hormonal status and Tanner stages.
36 months
Metabolic and endocrine changes
Tidsramme: 12 months
12 months
Metabolic and endocrine changes
Tidsramme: 24 months
24 months
Metabolic and endocrine changes
Tidsramme: 36 months
36 months
Inflammatory status
Tidsramme: 12 months
Measurement of serum inflammatory markers.
12 months
Inflammatory status
Tidsramme: 24 months
Measurement of serum inflammatory markers.
24 months
Inflammatory status
Tidsramme: 36 months
Measurement of serum inflammatory markers.
36 months
Cardiovascular abnormalities
Tidsramme: 12 months
12 months
Cardiovascular abnormalities
Tidsramme: 24 months
24 months
Cardiovascular abnormalities
Tidsramme: 36 months
36 months
Non-alcoholic fatty liver disease
Tidsramme: 12 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
12 months
Non-alcoholic fatty liver disease
Tidsramme: 24 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
24 months
Non-alcoholic fatty liver disease
Tidsramme: 36 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
36 months
Quality of life changes
Tidsramme: 12 months
12 months
Quality of life changes
Tidsramme: 24 months
24 months
Quality of life changes
Tidsramme: 36 months
36 months
Effects on sleep architecture
Tidsramme: 12 months
12 months
Effects on sleep architecture
Tidsramme: 24 months
24 months
Effects on sleep architecture
Tidsramme: 36 months
36 months
Behaviour changes
Tidsramme: 12 months
Measuring impulsivity and positive reward dominance with a computer task.
12 months
Behaviour changes
Tidsramme: 24 months
Measuring impulsivity and positive reward dominance with a computer task.
24 months
Behaviour changes
Tidsramme: 36 months
Measuring impulsivity and positive reward dominance with a computer task.
36 months
Brain development
Tidsramme: 12 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
12 months
Brain development
Tidsramme: 24 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
24 months
Brain development
Tidsramme: 36 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
36 months
Physical activity
Tidsramme: 6 months
Assessment of physical activity using a questionnaire and an accelerometer.
6 months
Physical activity
Tidsramme: 12 months
Assessment of physical activity using a questionnaire and an accelerometer.
12 months
Physical activity
Tidsramme: 24
Assessment of physical activity using a questionnaire and an accelerometer.
24
Physical activity
Tidsramme: 36 months
Assessment of physical activity using a questionnaire and an accelerometer.
36 months
Behavior towards food
Tidsramme: 6 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
6 months
Behavior towards food
Tidsramme: 12 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
12 months
Behavior towards food
Tidsramme: 24 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
24 months
Behavior towards food
Tidsramme: 36 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
36 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: LWE van Heurn, Professor, Maastricht University Medical Center
  • Ledende efterforsker: Yvonne Roebroek, PhD Student, Maastricht University Medical Center
  • Ledende efterforsker: Givan F Paulus, PhD Student, Spaarne Gasthuis, Haarlem

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. december 2011

Primær færdiggørelse (Forventet)

1. december 2022

Studieafslutning (Forventet)

1. december 2022

Datoer for studieregistrering

Først indsendt

22. juli 2010

Først indsendt, der opfyldte QC-kriterier

29. juli 2010

Først opslået (Skøn)

30. juli 2010

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

26. august 2021

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. august 2021

Sidst verificeret

1. august 2021

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • NL26279.068.09

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Fedme, sygelig

Kliniske forsøg med laparoscopic adjustable gastric band

Abonner